|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...5354555657585960616263...6768» |
- Increlex (mecasermin) / Ipsen
Enrollment change: IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=15, Completed, Sponsor: Bispebjerg Hospital
N=20 --> 15
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=43, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=20 --> 15 N=60 --> 43
- Enrollment change, Metastases: Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=148, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=60 --> 43 N=120 --> 148
- Trial completion, Metastases: Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=148, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=120 --> 148 Terminated --> Completed
- human allogeneic myeloid progenitor cells (CLT-008) / Cellerant Therap
Enrollment change, Post-transplantation: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy (clinicaltrials.gov) - Oct 4, 2012
P1, N=40, Recruiting, Sponsor: Cellerant Therapeutics
Terminated --> Completed N=22 --> 40
- | Trial initiation date: PROPPR: Pragmatic, Randomized Optimal Platelet and Plasma Ratios (clinicaltrials.gov) - Oct 3, 2012
P3, N=680, Completed, Sponsor: The University of Texas Health Science Center, Houston
N=22 --> 40 Initiation date: Mar 2012 --> Aug 2012
- Enrollment change: S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease (clinicaltrials.gov) - Oct 2, 2012
P=N/A, N=37, Completed, Sponsor: Southwest Oncology Group
Initiation date: Mar 2012 --> Aug 2012 N=500 --> 37
- Epogen (epoetin alfa) / Amgen
Enrollment change: Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=89, Completed, Sponsor: Jonsson Comprehensive Cancer Center
N=500 --> 37 N=180 --> 89
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., bendamustine / Generic mfg.
New P2 trial: Bendamustine, Lenalidomide (Revlimid (clinicaltrials.gov) - Oct 2, 2012
P2, N=50, Recruiting, Sponsor: Cantonal Hospital of St. Gallen
- | Beqvez (fidanacogene elaparvovec-dzkt) / Pfizer
Enrollment open, Gene therapy, Viral vector: Hemophilia B Gene Therapy With AAV8 Vector (clinicaltrials.gov) - Oct 2, 2012
P1/2, N=15, Recruiting, Sponsor: Spark Therapeutics, LLC
N=180 --> 89 Not yet recruiting --> Recruiting
- Trial completion: S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease (clinicaltrials.gov) - Oct 2, 2012
P=N/A, N=37, Completed, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=89, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial: Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant (clinicaltrials.gov) - Oct 1, 2012
P2, N=70, Recruiting, Sponsor: John Haslip
- Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases: Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P1, N=5, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=10 --> 5
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change, Metastases: Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=7, Completed, Sponsor: University of California, San Francisco
N=10 --> 5 N=10 --> 7
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg.
New P2 trial, Combination therapy: A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Oct 1, 2012
P2, N=20, Active, not recruiting, Sponsor: Celgene Corporation
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P1, N=5, Completed, Sponsor: University of California, San Francisco
N=10 --> 7 Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Metastases: Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=7, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=25, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 30, 2012
P2, N=0, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=36 --> 0
- ||| bortezomib / Generic mfg.
Clinical: Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=110, Recruiting, Sponsor: Oncotherapeutics
- || Enrollment closed: Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: University of Arkansas
N=36 --> 0 Recruiting --> Active, not recruiting
- ||||| bortezomib / Generic mfg.
New P2 trial: Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens (clinicaltrials.gov) - Sep 25, 2012
P2, N=52, Recruiting, Sponsor: Oncotherapeutics
- | NovoEight (turoctocog alfa) / Novo Nordisk
New P1 trial: Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A (clinicaltrials.gov) - Sep 24, 2012
P1, N=15, Completed, Sponsor: Novo Nordisk
- Promacta (eltrombopag) / Novartis
Enrollment open: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (clinicaltrials.gov) - Sep 24, 2012
P2, N=26, Recruiting, Sponsor: Fondazione Progetto Ematologia
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Inrebic (fedratinib) / BMS
New P2 trial: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly (clinicaltrials.gov) - Sep 23, 2012
P2, N=8, Completed, Sponsor: Sanofi
- Trial completion, Metastases: CI-994 in Treating Patients With Advanced Myeloma (clinicaltrials.gov) - Sep 20, 2012
P2, N=6, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| melphalan / Generic mfg., carfilzomib / Generic mfg.
BRCA Biomarker: Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Sep 19, 2012
P1/2, N=58, Recruiting, Sponsor: Medical University of South Carolina
- ciprofloxacin oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Trial termination, Combination therapy, Monotherapy: Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=351, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- ciprofloxacin oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Enrollment change, Combination therapy, Monotherapy: Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=351, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual N=530 --> 351
- | piperacillin sodium/tazobactam sodium / Generic mfg., vancomycin / Generic mfg.
Enrollment change: Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count (clinicaltrials.gov) - Sep 19, 2012
P3, N=859, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=530 --> 351 N=500 --> 859
- New P1 trial: Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 19, 2012
P1, N=18, Recruiting, Sponsor: OHSU Knight Cancer Institute
- ||||| dexamethasone / Generic mfg., pomalidomide / Generic mfg.
Combination therapy: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (clinicaltrials.gov) - Sep 19, 2012
P3, N=455, Active, not recruiting, Sponsor: Celgene Corporation
N=500 --> 859 Recruiting --> Active, not recruiting
- | piperacillin sodium/tazobactam sodium / Generic mfg., vancomycin / Generic mfg.
Trial completion: Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count (clinicaltrials.gov) - Sep 19, 2012
P3, N=859, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| BeneFix (nonacog alfa) / Pfizer
Enrollment open, Adverse events: Registry For Patients Treated With BeneFix In Usual Care Setting In Germany (clinicaltrials.gov) - Sep 17, 2012
P4, N=100, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- ||| Ojjaara (momelotinib) / GSK
Enrollment closed: Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) (clinicaltrials.gov) - Sep 17, 2012
P2, N=120, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- | Enrollment closed: Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy (clinicaltrials.gov) - Sep 17, 2012
P2, N=18, Active, not recruiting, Sponsor: Cristina Gasparetto
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- Farydak (panobinostat) / Secura Bio
Clinical: Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 11, 2012
P1, N=36, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting N=15 --> 36
- bortezomib / Generic mfg., dexamethasone / Generic mfg., melphalan / Generic mfg.
Enrollment closed: Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis (clinicaltrials.gov) - Sep 9, 2012
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=15 --> 36 Recruiting --> Active, not recruiting
- ||| Trial completion: Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (clinicaltrials.gov) - Sep 6, 2012
P=N/A, N=282, Completed, Sponsor: Novo Nordisk
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- | Biostate (factor VIII/von Willebrand factor) / CSL Behring
Enrollment closed: Study of Biostate (clinicaltrials.gov) - Sep 6, 2012
P3, N=24, Active, not recruiting, Sponsor: CSL Behring
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- dovitinib (TKI258) / Novartis, Oncoheroes
New P1 trial, Combination therapy: Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 5, 2012
P1, N=0, Withdrawn, Sponsor: University of Florida
- Trial withdrawal: Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients (clinicaltrials.gov) - Sep 4, 2012
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Enrollment change: Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients (clinicaltrials.gov) - Sep 4, 2012
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=70 --> 0
- | bortezomib / Generic mfg., melphalan / Generic mfg.
Trial completion: Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants (clinicaltrials.gov) - Sep 3, 2012
P2, N=30, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=70 --> 0 Active, not recruiting --> Completed
- Nplate (romiplostim) / Amgen, Kyowa Kirin
New P2 trial: Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - Aug 29, 2012
P2, N=14, Recruiting, Sponsor: New York University School of Medicine
- ||||||| vatreptacog alfa (NN 1731) / Novo Nordisk
Trial completion: Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors (clinicaltrials.gov) - Aug 28, 2012
P3, N=72, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial initiation date: Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer (clinicaltrials.gov) - Aug 28, 2012
P2, N=24, Completed, Sponsor: Northside Hospital, Inc.
Active, not recruiting --> Completed Initiation date: Nov 2006 --> Apr 2007
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer (clinicaltrials.gov) - Aug 28, 2012
P2, N=24, Completed, Sponsor: Northside Hospital, Inc.
Initiation date: Nov 2006 --> Apr 2007 Active, not recruiting --> Completed
- ||| Zydelig (idelalisib) / Gilead
Trial completion: Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Aug 28, 2012
P1, N=192, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed